ArticleInternational journal of clinical oncology2026

Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma.

Risa Nishiyama et al.PubMed ↗Publisher ↗

No numbers read from the abstract.